Sibrotuzumab Biosimilar – Anti-FAP mAb – Research Grade

Introduction

Sibrotuzumab Biosimilar, also known as Anti-FAP mAb, is a monoclonal antibody that targets the fibroblast activation protein (FAP). FAP is a cell surface protein that is highly expressed in cancer-associated fibroblasts, making it an attractive therapeutic target for various types of cancer. In this article, we will discuss the structure, activity, and potential applications of Sibrotuzumab Biosimilar in cancer research.

Structure of Sibrotuzumab Biosimilar

Sibrotuzumab Biosimilar is a recombinant humanized monoclonal antibody that is produced using a combination of genetic engineering and cell culture techniques. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to FAP, while the constant region determines the antibody’s effector functions.

The antibody has a molecular weight of approximately 150 kDa and a half-life of 10-14 days in the human body. It is stable at physiological pH and temperature, making it suitable for therapeutic use.

Activity of Sibrotuzumab Biosimilar

Sibrotuzumab Biosimilar binds specifically to FAP, a protein that is overexpressed in the tumor stroma of various types of cancer, including breast, lung, and pancreatic cancer. FAP is involved in tumor growth, invasion, and metastasis, making it an attractive target for cancer therapy.

Upon binding to FAP, Sibrotuzumab Biosimilar can inhibit FAP’s enzymatic activity, which is responsible for promoting tumor growth and metastasis. It can also trigger an immune response, leading to the destruction of FAP-expressing cells by the body’s immune system.

Applications of Sibrotuzumab Biosimilar

Sibrotuzumab Biosimilar has shown promising results in preclinical and clinical studies as a potential therapeutic agent for various types of cancer. Some of its potential applications include:

Treatment of solid tumors Sibrotuzumab Biosimilar has been studied as a potential treatment for solid tumors, such as breast, lung, and pancreatic cancer. In a phase II clinical trial, it showed promising results in combination with chemotherapy in patients with advanced pancreatic cancer, leading to improved overall survival and progression-free survival.

Targeted therapy

Due to its specific binding to FAP, Sibrotuzumab Biosimilar has the potential to be used as a targeted therapy for cancer. This means that it can selectively target and destroy cancer cells while sparing healthy cells, reducing the risk of side effects.

Imaging agent

Sibrotuzumab Biosimilar can also be used as an imaging agent to detect FAP-expressing tumors. This can aid in the diagnosis and staging of cancer, as well as monitoring the response to therapy.

Research tool

In addition to its potential therapeutic applications, Sibrotuzumab Biosimilar can also be used as a research tool to study the role of FAP in cancer progression and to develop new treatments targeting FAP.

Conclusion

In summary, Sibrotuzumab Biosimilar is a promising monoclonal antibody that targets FAP, a protein that is overexpressed in various types of cancer. Its specific binding to FAP and its potential to inhibit FAP’s enzymatic activity make it a promising therapeutic agent for cancer. Further research and clinical trials are needed to fully understand its potential and to bring this antibody to the market for the benefit of cancer patients.